A new sclerotherapy technique by slow mechanical infusion of sclerosant was validated for treatment of microcystic lymphatic malformation (mLM). Materials and Methods: Seventeen consecutive patients with mLM in extremities, cervicofacial area, and trunk were included (21.8 ± 21.5 years old, male:female = 5:12). All patients diagnosed as mLM were included. A total 4-32 mL 20-38% OK-432 solution was mechanically infused at the rate of 10 mL/hour into the mLM lesions. The treatment effect was estimated clinic-radiologically at the 4-month follow-up. Repeated sclerotherapy followed in the 6th month, if required. The therapeutic effect was evaluated using quantitative ultrasonographic examination including soft tissue thickness, cyst size and number. Results: In 17 patients, total 31 infusion sclerotherapy sessions were performed and monitored for 425 ± 266 days. Fifteen patients (88%) showed improvement in all symptoms, signs, and ultrasonographic findings. In all cases, at least one finding presented improvement. The maximal number of cysts per ultrasonographic window and maximal diameter of the largest cyst decreased by 57 ± 57% and 51 ± 67%, respectively (p = 0.102, 0.004). The soft tissue thickness decreased by 18 ± 15% (p < 0.01). No significant complications such as distal lymphedema or skin necrosis occurred. Conclusion: Infusion sclerotherapy is a safe and effective treatment technique for microcystic LM, with improved outcome.
INTRODUCTION
Congenital vascular anomalies including lymphatic malformation (LM) are described by different names from diverse viewpoints. LM has been described as cystic hygroma or lymphangioma based on physical and pathological features. In 1982, Mulliken and Glowacki (1) suggested a reasonable classification for congenital vascular anomalies including LM. Subsequently in 1996, the International Society for the Study of Vascular Anomalies acknowledged their nomenclature as a standard classification of congenital vascular anomalies (2) . Recently, LM is further classified as microcystic, macrocystic, and mixed forms, according to the size of the abnormal lymphatic cavity. Microcystic LM is defined as a single or multiple lymphatic cysts or channels smaller than 2 cm 3 in size (3) .
Clinical diagnosis of microcystic LM usually depends on its features including non-compressible tissue consistency during palpation, typical dermal lesions such as vesicles or maculopapular lesions, soft tissue mass, lymph leakage, hemorrhage, and pain (4) . Ultrasonography (USG) or magnetic resonance imaging jksronline.org J Korean Soc Radiol 2016;74(1): [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] (MRI) of LM aims to achieve more confirmative diagnoses and evaluate the extent and subtypes of the LM (5) . In contrast to macrocystic LM showing single or multiple separate or interconnected thin-walled cysts, microcystic LM presents smaller irregular cysts with microscopic abnormal lymphatic channels. In the MRI, the microscopic abnormal lymphatic channels may appear as a solid lesion of high fluid content without an evident contrastenhancement. In USG, the abnormal microscopic lymphatic channels usually appear as a hyperechoic infiltrative solid soft tissue lesion.
Historically, LM has been treated by surgery (5) . Recently, direct puncture sclerotherapy has been used as an initial treatment of choice and achieved more favorable results than surgical treatment (3) . In a prospective survey using OK-432 (Picibanil ® , Chugai Pharmaceutical Co., Tokyo, Japan) as a sclerosant, the outcome of sclerotherapy was rated high in macrocystic LM and low in mixed LM. Whereas, in this prospective survey, no microcystic LM responded properly to the sclerotherapy (6) . A study with repeated sclerotherapy using bleomycin A5 hydrochloride presented 78.57% effectiveness in a microcystic LM cohort.
However, the response was clinically graded without quantitative analysis (7) . A study with direct puncture sclerotherapy using 20 mg/mL doxycycline reported complete ablation of 179 microcysts without presenting effectiveness per patient (8) . As for sclerotherapy of microcystic LM, diverse levels of its effectiveness have been reported by lesion characteristics, treatment methods, sclerosants, and result evaluation criteria (5) (6) (7) (9) (10) (11) (12) (13) (14) .
Due to the multiple small isolated cysts and since microscopic dilatation of lymphatic channels may be free from infiltration of the manually injected sclerosant during sclerotherapy, the therapeutic response of microcystic LM might not be as good and the recurrence rate might be higher than in macrocystic LM. We introduced a new sclerotherapy protocol using a slow mechanical infusion technique to increase the effectiveness of sclerotherapy for microcystic LM. The new protocol was applied to microcystic LM cases containing both infiltrative channel-type and microcystic lesions. In this study, a mid-term outcome of the new sclerotherapy technique, "infusion sclerotherapy", was evaluated retrospectively.
MATERIALS AND METHODS
The study protocol was approved by our Institutional Review Board (IRB). Patients' informed consents were waived by IRB due to the retrospective observational nature of the study.
Subjects
All consecutive 17 patients for the year 2012 were enrolled in the subject group without exclusion. Due to an exchange of sclerosant supply, latter data were not included in the study group.
The age of subjects ranged from 1 to 68 years of age with an average of 18.6 years. The male to female ratio was 5:12. The anatomical locations of the microcystic LM were head and neck (n = 7), lower extremity (n = 7), trunk (n = 1), and upper extremity (n = 2). The subjects' chief complaints comprised of dermal lesions such as vesicular maculopapular lesions (n = 6), swelling (n = 4), pain (n = 5), and leakage of lymph fluid or hemorrhage (n = 2).
The demographic and clinical data of all subjects were summarized in Table 1 .
Diagnosis
Microcystic LM was diagnosed based on clinical and imaging features by an interventional radiologist, vascular surgeons, plastic surgeons, orthopedic surgeons, and dermatologists in our in- Mild Imp Mild Imp FUI = follow-up interval by days, Imp = improvement, Sn = clinically observed sign, SSC = sclerotheraphy session count, Sx = subjective symptom jksronline.org If either improved or persistent cases were LM with accessible cysts by USG-guided puncture, additional infusion sclerotherapy was usually recommended. No further sclerotherapy was recommended in aggravated cases based on an interdisciplinary consensus, since it was regarded as an ineffective therapy. In cases of multiple sclerotherapies, the initial and the last clinical and ultrasonographic findings were compared to validate the infusion sclerotherapy.
Statistical Analysis
All statistics were computed using SPSS version 21.0.0.0 (SPSS Inc., Chicago, IL, USA). Quantitative data were compared by paired t-test. A p-value < 0.05 was considered statistically significant. (p < 0.01) (Fig. 1) . The 3 ultrasonographic check points showed asynchronously, different interval changes per subject ( Table 2) . The histological examination using classic hematoxylin and eosin stain, special staining for elastic fiber, and immunohistochemistry for D2-40, Glut-1, CD31, SMA, and Prox-1 presented a LM.
RESULTS
No other early complication was noted in this study. Also, no The infusion was done by an electromechanical infusion pump at the speed of 10 mL/hr. C. In 2 minutes after infusion start, the sclerosant infiltrates into adjacent microcysts and channels (arrows). D. The second lesion area was punctured and sclerosant was infused in parallel. In 21 minutes after initial infusion start, the lower lesion is fully filled by sclerosant with spill to adjacent normal-looking lymphatic channels (arrowheads). The newer upper lesion shows numerous microcysts interconnected by small channels (arrows). E. In 29 minutes, more microcysts in further distance are filled by sclerosant (arrow). F. In 50 minutes of infusion, no newly filled microcyst is noted and adjacent normal-looking small lymphatic channels are opacified (arrow). In lower lesion, opacification of normal lymphatic vessel is not progressed due to infusion stop (arrowhead). G. Ultrasonography was performed in 1 year after the infusion sclerotherapy. In same scope and plane as the initial image (A), cystic and channel lesions (arrows) show decreased sizes. Also, clinical symptom and sign are improved markedly. 
DISCUSSION
In this study, valid results of the infusion sclerotherapy for microcystic and channel-type LM were achieved. Microcystic LM is reported to be less effective to percutaneous sclerotherapy using diverse sclerosants. A noticeable report using several sclerosants presented complete responses in 17% of 15 cases with microcystic LM. However, in the same study, the success rate was markedly lower than macrocystic LM (47%) (15) . A main reason for lower success rate of sclerotherapy in microcystic LM is conceived to be non-uniform spread of sclerosant through complex lesion geometry with less connectivity. The rationale of the present study was that slow constant infusion could improve uniformity of drug delivery through the lesion by avoiding earlier rup- Marked Imp AC = almost complete, C# = maximal number of cysts in a single US window, Dmx = maximal diameter of the largest cyst (mm), Imp = improvement, N/A = not available, STth = soft tissue thickness from lesion to dermal surface (mm), US = ultrasonography Symptom Sign Ultrasonography Fig. 3 . Infusion sclerotherapy presented an improvement of symptoms, signs, and image findings in 16, 16, and 16 cases among 17 patients, respectively. The definition of microcystic LM was suggested as LM comprising of single or multiple cysts smaller than 2 cm 3 in volume.
Lesions with a cyst larger than this criterion were classified as a macrocystic LM. Combined macrocystic and microcystic LM was nominated as mixed type LM (3). In parallel, another classification guideline using the diameter of the largest cyst within LM has been suggested. The maximal diameter of cysts less than 2 cm was suggested as microcystic LM (7, 16) . In this study, mi- On the demographic data for our subject groups, more females than males were included in contrast to the report of no sexual predilection (17) . In this study, the most prevalent lesion sites were head, neck, and lower extremity, which was concordant with a previous report (18) . In the literature, the prevalent age of LM was reported as infancy and young childhood (80-90% before the age of 2 years) (18) . Whereas, our entire subject cohort showed a mean age of 18.6 years and only 2 subjects were younger than the age of 2 years. Since our subject group was solely comprised of microcystic LM cases actually treated by sclero- Several drugs or chemicals have been used as agents for sclerotherapy of LM, including bleomycin, doxycycline, ethanol, and OK-432 (3, (19) (20) (21) . Despite the complications by penetration into adjacent tissue, ethanol has been used as the strongest sclerosant for more definite results (10, 22, 23) . Bleomycin was introduced for LM sclerotherapy in very early trials (24) . However, it may cause fatal complication such as pulmonary interstitial fibrosis or hypersensitivity (25, 26 A major limitation of this study was that the decision of symptoms and signs was performed subjectively by patients and surroundings, including the doctors. However, since the improvement was based on consensus of a multi-disciplinary group, objectivity might be preserved. The second limitation was the ultrasonographic improvement of microcystic LM was decided by radiologists who were not blinded to sclerotherapy information.
However, introduction of a systematic quantitative evaluation of image findings attempted to minimize this limitation. The third limitation was that the OK-432 is not available for world-wide use. Although availability of the OK-432 is limited to some countries where out institute locates, its effectiveness as a sclerosant is accepted in the literature (13) . Furthermore, in this study, the drug delivery technique was a main focus rather than any specific property of OK-432. The fourth limitation was that the sclerosant was an emulsion of lipophilic lipiodol and hydrophilic OK-432 that was infused for a long time. During delayed infusion, both components should be separated with layering. To maintain the concentration of OK-432 during delayed infusion, in this study, the layer between OK-432 and lipiodol was adjusted to the sy-ringe outlet orifice. In addition, due to well-acknowledged embolic effect of lipiodol, evaluation of pure benefit of infusion sclerotherapy may be limited as compared to reported data with hydrophilic contrast media (16, 28, 29) . The fifth limitation was that all the follow-up imaging was performed using USG alone.
Not every patient received MR exam for their routine follow-up imaging due to financial burden in our country. The objectiveness of ultrasonographic decision may have limitation for accurate quantitative measurement of interval change. In this study, ultrasonographic evaluation was based on qualitative and semiquantitative ways with a systematic stratification to minimize subjective bias by observer. The last limitation was that the infusion sclerotherapy technique was applied only to the OK-432 cohort due to the size of cohort in our institute. The feasibility evaluation for the infusion sclerotherapy should be continued in cohorts with the other sclerosants.
In conclusions, a new sclerotherapy technique for microcystic LM i.e., infusion sclerotherapy was suggested and verified. Infusion sclerotherapy was a safe and effective treatment technique for microcystic LM, with favorable outcome. For more extensive and safe application of the infusion sclerotherapy, more delicate guideline should be developed through more extensive application. In addition, a prospective randomized trials comparing the infusion sclerotherapy and conservative technique is expected.
